Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Epithelial Ovarian Cancer.
Castle Biosciences' TissueCypher test predicts a patient’s risk of progression from Barrett’s oesophagus to oesophageal ...
Older diagnostic methods, such as tissue culture and serology, have been replaced with more advanced molecular techniques, such as PCR and reverse-transcriptase PCR, nucleic acid sequence-based ...
Objectives To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA).
(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced ...
Live Science on MSN5d
Healthy breast cells can look like invasive cancer, complicating early diagnosisScientists found that healthy women can carry genetic changes in their breast cells that are thought to be characteristic of ...
A multi-institutional team of scientists has developed a free, publicly accessible resource to aid in classification of patient tumor samples based on distinct molecular features identified by The ...
This approach achieves high accuracy and offers a rapid, cost-effective alternative to current methods that rely on expensive molecular assays ... based on DNA and RNA extracted from tissue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback